Johnson & Johnson and AbbVie bought a combined $55m of stock as the biopharmaceutical company, already listed in Europe, went public on Nasdaq.

Bank of Ireland Seed and Early Stage Fund plans to divest 25% of its portfolio in the next year, beginning with medical device developer NeoSurgical.

Novo, GlaxoSmithKline and Merck-backed molecular profiling platform HTG offered almost 3.6 million shares priced at $14 each.

Pet medicine developer Jaguar Animal Health, backed by Napo Pharmaceuticals, raised $20m after receiving $2.2m of venture funding.

Twitter revealed in its earnings report that it spent a combined $86.6m to acquire William Morris Endeavor-backed Niche and Periscope earlier this year.

Novo Seeds, Lundbeck, Merck and Astellas all exited EpiTherapeutics after it was acquired by biopharmaceutical firm Gilead.

Galapagos has increased the target for its upcoming IPO on Nasdaq to $230m, while $55m of the stock could be bought by AbbVie and Johnson & Johnson.

Novo Seeds, Lundbeck, Merck and Astellas all exited EpiTherapeutics after it was acquired by biopharmaceutical firm Gilead.

The wearable fitness device maker has raised $83m in funding from investors including SoftBank and Qualcomm.